Chapter

Chemotherapy for metastatic prostate cancer

Cora N Sternberg and Guru Sonpavde

in Systemic Treatment of Prostate Cancer

Published on behalf of Oxford University Press

ISBN: 9780199561421
Published online May 2011 | e-ISBN: 9780199607372 | DOI: http://dx.doi.org/10.1093/med/9780199561421.003.0007

Series: Oxford Oncology Library

Chemotherapy for metastatic prostate cancer

Show Summary Details

Preview

• Docetaxel-based chemotherapy has been shown to modestly extend life, relieve pain, and improve the quality of life in patients with metastatic castration-resistant prostate cancer • Current trials are attempting to build on the backbone of docetaxel by combining it with novel biologic agents • Trials are also investigating the role of docetaxel for earlier stages of prostate cancer • No standard second-line chemotherapy exists and such patients are candidates for trials. The increased understanding of the mechanisms of progressive castration-resistant prostate cancer is being translated into an increasing pipeline of novel therapies.

Chapter.  3410 words. 

Subjects: Clinical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.